Perioperative immunotherapy in stage IB-III non-small cell lung cancer: a critical review of its rationale and considerations
Jae Kyeom Sim, Juwhan Choi, Sung Yong Lee
Korean J Intern Med. 2023;38(6):787-796. Published online 2023 Nov 1 DOI: https://doi.org/10.3904/kjim.2023.345
Citations to this article as recorded by 
Serial KL-6 Changes in PD-1/PD-L1 Inhibitor-Related Pneumonitis in Non-small Cell Lung Cancer: A Single-Center Prospective Pilot Study
Jae Kyeom Sim, Juwhan Choi, Sung Won Chang, Sang Hyuk Kim, Jee Youn Oh, Kyung Hoon Min, Gyu Young Hur, Hwan Seok Yong, Jae Jeong Shim, Sung Yong Lee
Tuberculosis and Respiratory Diseases.2026; 89(2): 257. CrossRef
Perioperative immunotherapy for nonsmall cell lung cancer
Jingya Huang, Wenyuan Li, Hui Guo
Current Opinion in Oncology.2025; 37(1): 63. CrossRef
Efficacy and adverse events of immune checkpoint inhibitors: evidence from non-small cell lung cancer and gastric cancer in Korea and Japan
Mc Neil Valencia, Zeeshan Abbas, Seung Won Lee
Precision and Future Medicine.2025; 9(1): 15. CrossRef
Current Status of Immunotherapy in Resectable Lung Cancer
Paulami Deshmukh, Omar Abughanimeh, Apar Kishor Ganti
Indian Journal of Surgical Oncology.2025;[Epub] CrossRef
Perioperative immunotherapy for stage II-III non-small cell lung cancer: a meta-analysis base on randomized controlled trials
Anping Yu, Feng Fu, Xiongying Li, Mengxin Wu, Meijian Yu, Wenxiong Zhang
Frontiers in Oncology.2024;[Epub] CrossRef
Neoadjuvant and Adjuvant Immunotherapy in Resectable NSCLC
Evangelia Bogatsa, George Lazaridis, Chrysoula Stivanaki, Eleni Timotheadou
Cancers.2024; 16(9): 1619. CrossRef